These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29968076)

  • 41. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biomarkers of response to PD-1/PD-L1 inhibition.
    Maleki Vareki S; Garrigós C; Duran I
    Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?].
    Bersanelli M; Buti S; De Giorgi U; Di Maio M; Giannarelli D; Banna GL
    Recenti Prog Med; 2018 Nov; 109(11):540-546. PubMed ID: 30565573
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 46. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
    Hashemi-Sadraei N; Sikora AG; Brizel DM
    Am Soc Clin Oncol Educ Book; 2016; 35():e277-82. PubMed ID: 27249733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
    Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
    Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three Drugs Approved for Urothelial Carcinoma by FDA.
    Cancer Discov; 2017 Jul; 7(7):659-660. PubMed ID: 28546286
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emerging biomarkers for PD-1 pathway cancer therapy.
    Lim JS; Sundar R; Chénard-Poirier M; Lopez J; Yap TA
    Biomark Med; 2017 Jan; 11(1):53-67. PubMed ID: 27936870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Checkpoint inhibitors: outstanding efficacy but at what cost?
    Klastersky JA
    Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
    [No Abstract]   [Full Text] [Related]  

  • 54. Immune checkpoint inhibitors in lung cancer: an update.
    Sullivan K; Preeshagul I; Budman D; Seetharamu N
    Future Oncol; 2017 May; 13(11):955-959. PubMed ID: 28481150
    [No Abstract]   [Full Text] [Related]  

  • 55. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune Checkpoints as a Target for Colorectal Cancer Treatment.
    Passardi A; Canale M; Valgiusti M; Ulivi P
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635639
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade.
    Voong KR; Naidoo J; Ettinger DS
    Clin Adv Hematol Oncol; 2017 Aug; 15(8):615-625. PubMed ID: 28949949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
    Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
    J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.